Literature DB >> 25714967

Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders.

Mohammad A Kamal1, Gohar Mushtaq, Nigel H Greig.   

Abstract

Aberrant expression of microRNAs (miRNAs) has been implicated in various neurological disorders (NDs) of the central nervous system such as Alzheimer disease, Parkinson's disease, Huntington disease, amyotrophic lateral sclerosis, schizophrenia and autism. If dysregulated miRNAs are identified in patients suffering from NDs, this may serve as a biomarker for the earlier diagnosis and monitoring of disease progression. Identifying the role of miRNAs in normal cellular processes and understanding how dysregulated miRNA expression is responsible for their neurological effects is also critical in the development of new therapeutic strategies for NDs. miRNAs hold great promise from a therapeutic point of view especially if it can be proved that a single miRNA has the ability to influence several target genes, making it possible for the researchers to potentially modify a whole disease phenotype by modulating a single miRNA molecule. Hence, better understanding of the mechanisms by which miRNA play a role in the pathogenesis of NDs may provide novel targets to scientists and researchers for innovative therapies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25714967      PMCID: PMC5878050          DOI: 10.2174/1871527314666150225143637

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  103 in total

1.  Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP.

Authors:  Mithun Sinha; Jayeeta Ghose; Eashita Das; Nitai P Bhattarcharyya
Journal:  Biochem Biophys Res Commun       Date:  2010-05-06       Impact factor: 3.575

2.  A microRNA array reveals extensive regulation of microRNAs during brain development.

Authors:  Anna M Krichevsky; Kevin S King; Christine P Donahue; Konstantin Khrapko; Kenneth S Kosik
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

Review 3.  The evolution of gene regulation by transcription factors and microRNAs.

Authors:  Kevin Chen; Nikolaus Rajewsky
Journal:  Nat Rev Genet       Date:  2007-02       Impact factor: 53.242

Review 4.  MicroRNAs: key players in carcinogenesis and novel therapeutic targets.

Authors:  A H F Mirnezami; K Pickard; L Zhang; J N Primrose; G Packham
Journal:  Eur J Surg Oncol       Date:  2008-07-21       Impact factor: 4.424

5.  Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls.

Authors:  Lucía F Cardo; Eliecer Coto; Lorena de Mena; Renée Ribacoba; Germán Moris; Manuel Menéndez; Victoria Alvarez
Journal:  J Neurol       Date:  2013-03-30       Impact factor: 4.849

6.  A MicroRNA feedback circuit in midbrain dopamine neurons.

Authors:  Jongpil Kim; Keiichi Inoue; Jennifer Ishii; William B Vanti; Sergey V Voronov; Elizabeth Murchison; Gregory Hannon; Asa Abeliovich
Journal:  Science       Date:  2007-08-31       Impact factor: 47.728

7.  Heterogeneous dysregulation of microRNAs across the autism spectrum.

Authors:  Kawther Abu-Elneel; Tsunglin Liu; Francesca S Gazzaniga; Yuhei Nishimura; Dennis P Wall; Daniel H Geschwind; Kaiqin Lao; Kenneth S Kosik
Journal:  Neurogenetics       Date:  2008-06-19       Impact factor: 2.660

8.  MicroRNAs modulate hematopoietic lineage differentiation.

Authors:  Chang-Zheng Chen; Ling Li; Harvey F Lodish; David P Bartel
Journal:  Science       Date:  2003-12-04       Impact factor: 47.728

Review 9.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

Review 10.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

View more
  13 in total

1.  Excessive expression of miR-27 impairs Treg-mediated immunological tolerance.

Authors:  Leilani O Cruz; Somaye Sadat Hashemifar; Cheng-Jang Wu; Sunglim Cho; Duc T Nguyen; Ling-Li Lin; Aly Azeem Khan; Li-Fan Lu
Journal:  J Clin Invest       Date:  2017-01-09       Impact factor: 14.808

Review 2.  miRNA degradation in the mammalian brain.

Authors:  Chun K Kim; Toni R Pak
Journal:  Am J Physiol Cell Physiol       Date:  2020-08-12       Impact factor: 4.249

Review 3.  Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview.

Authors:  Khurshid Ahmad; Mohammad Hassan Baig; Gohar Mushtaq; Mohammad Amjad Kamal; Nigel H Greig; Inho Choi
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

4.  A hidden threshold in motor neuron gene networks revealed by modulation of miR-218 dose.

Authors:  Neal D Amin; Gokhan Senturk; Giancarlo Costaguta; Shawn Driscoll; Brendan O'Leary; Dario Bonanomi; Samuel L Pfaff
Journal:  Neuron       Date:  2021-08-26       Impact factor: 18.688

5.  Clustering of Alzheimer's and Parkinson's disease based on genetic burden of shared molecular mechanisms.

Authors:  Mohammad Asif Emon; Ashley Heinson; Ping Wu; Daniel Domingo-Fernández; Meemansa Sood; Henri Vrooman; Jean-Christophe Corvol; Phil Scordis; Martin Hofmann-Apitius; Holger Fröhlich
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

Review 6.  miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.

Authors:  Gohar Mushtaq; Nigel H Greig; Firoz Anwar; Mazin A Zamzami; Hani Choudhry; Munvar M Shaik; Ian A Tamargo; Mohammad A Kamal
Journal:  Med Chem       Date:  2016       Impact factor: 2.745

Review 7.  Emerging preclinical pharmacological targets for Parkinson's disease.

Authors:  Sandeep Vasant More; Dong-Kug Choi
Journal:  Oncotarget       Date:  2016-05-17

8.  Identifying and Exploiting Potential miRNA-Disease Associations With Neighborhood Regularized Logistic Matrix Factorization.

Authors:  Bin-Sheng He; Jia Qu; Qi Zhao
Journal:  Front Genet       Date:  2018-08-07       Impact factor: 4.599

9.  miR‑223‑3p/TIAL1 interaction is involved in the mechanisms associated with the neuroprotective effects of dexmedetomidine on hippocampal neuronal cells in vitro.

Authors:  Qi Wang; Hongmei Yu; Hong Yu; Meina Ma; Yali Ma; Rui Li
Journal:  Mol Med Rep       Date:  2018-12-11       Impact factor: 2.952

10.  TLHNMDA: Triple Layer Heterogeneous Network Based Inference for MiRNA-Disease Association Prediction.

Authors:  Xing Chen; Jia Qu; Jun Yin
Journal:  Front Genet       Date:  2018-07-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.